By Topic
Is Tamboran Resources Corporation (ASX: TBN) Uptrend Still Intact Following Its Pullback to Support?
Tamboran Resources is a pre-production shale gas developer in the Beetaloo Basin, advancing toward first gas in 2026. Strong drilling results, contracts, and infrastructure progress support its uptrend, though risks remain around execution, funding, and market access beyond initial supply agreements.
Has Tivan (ASX: TVN) Formed a Sustainable Long-Term Floor?
Tivan (ASX: TVN) develops critical minerals across Australia and Timor-Leste, led by the Speewah Fluorite project. Following a post-feasibility sell-off and rising cash burn, the stock faces a neutral-to-bearish technical outlook ahead of its late-2026 Final Investment Decision.
SRJ Technologies (ASX: SRJ) Explodes Higher as Contract Wins Ignite Buying Frenzy
SRJ Technologies has attracted strong investor interest following the securing of multiple energy-sector contracts, including major UAE robotic inspection projects. Growing adoption of BoltEx® technology, expanding Middle East operations, and a strengthening recurring revenue pipeline have boosted confidence in the company's growth outlook.
Can Zip Co (ASX: ZIP) Maintain Its Breakout Momentum to Clear Near-Term Resistance?
Zip Co is recovering from 2026 lows on record earnings, a buyback, and US growth via Stripe. Technically, it broke a downtrend with support near $2.00. Key risks: credit quality, US concentration, and competition.
Is Vault Minerals (ASX: VAU) Building a Base at Key Technical Support After Its 2025 Peak?
Vault Minerals, an ASX-listed mid-tier gold producer, is testing key long-term support after a 2025 peak. Despite strong assets and growth plans, merger uncertainty, weaker guidance, cost pressures, and gold-price sensitivity have weighed on sentiment, while technicals suggest base formation.
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.
...